{"id":294,"date":"2021-01-11T01:00:00","date_gmt":"2021-01-11T09:00:00","guid":{"rendered":"https:\/\/caam.tech\/?p=294"},"modified":"2022-04-14T17:34:26","modified_gmt":"2022-04-15T00:34:26","slug":"caamtech-synthesizes-3-more-psilocybin-alternatives","status":"publish","type":"post","link":"https:\/\/caam.tech\/caamtech-synthesizes-3-more-psilocybin-alternatives\/","title":{"rendered":"CaaMTech Synthesizes 3 More Psilocybin Alternatives"},"content":{"rendered":"\n
CaaMTech\u2019s latest publication, \u201cPsilacetin derivatives: the methyl-ethyl, methyl-allyl and di\u00adallyl variants of the psilocin prodrug<\/a>,\u201d reveals three novel psilocin prodrug<\/a> variants synthesized by CaaMTech. Psilocin prodrugs may offer practical advantages over psilocybin and could clear some of the roadblocks to mainstream access to psychedelic medicines. The three novel tryptamines are the latest drugs from CaaMTech\u2019s unmatched library of next-generation psychedelics.<\/p>\n\n\n\n \u201cWhen we surveyed the state of the art in 2017, there were only a few dozen psychedelic tryptamines that had ever<\/em> been made,\u201d explained Dr. Andrew Chadeayne<\/a>, CaaMTech CEO. \u201cOnly a few of them were purified and fully characterized, which limited all downstream research and development.\u201d<\/p>\n\n\n\n Psilocin is the active metabolite of psilocybin, the psychedelic compound in \u201cmagic mushrooms.\u201d Psilocybin, a prodrug of psilocin, has recently drawn increasing attention for its medicinal properties. Other psilocin prodrugs offer the same benefits as psilocybin, while providing other practical advantages, such as an optimized duration of action. These advantages could provide the key to overcoming hurdles psychedelic medicines face on the road to widespread clinical adoption and public accessibility.<\/p>\n\n\n\n